Products for Research Use Only

HDAC-IN-4

CAT: 0013-GTR19160740-01Size: 200 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0013-GTR19160740-01Size:200 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
A histone deacetylase (HDAC) inhibitor, extracted from patent WO/2007045844 A1. (In Vitro) :Zabadinostat has been tested in vitro in colon, lung, non-Hodgkin lymphoma, and myeloma cell lines with IC50s ranged from 0.2 to 15 μM. (In Vivo) :Zabadinostat substantially reduces tumor size in murine xenograft lung (A549a) and colon (HT29) models at a dose of 50 mg/kg. Tumor reductions are found to be associated with increased histone acetylation and decreased HDAC enzyme activity.For Zabadinostat, after oral dosing in murine and canine models, peak plasma concentrations (Cmax) are reached 1 to 2 hours after the dose and terminal half‐lives are 6 hours and 8 hours, respectively. After murine oral [14C]-Zabadinostat at a dose of 1.6 mg/kg (4 μmol/kg), tissue radioactivity peaked 3 to 6 hours after the dose and declined slowly thereafter with Zabadinostat‐related material still present in tissue 21 days after the dose.
CAS Number
934828-12-3
Product Name Alternative
AZD 9468
Field of Research
Epigenetics & Chromatin
Purity
>98% (HPLC)
Solubility
DMSO: ≥ 31 mg/mL
Smiles
O=C (NC1=CC=CC=C1N) C2=CC=C (C3CCN (CC4=CN (C) N=C4C) CC3) C=C2
Molecular Formula
C24H29N5O
Molecular Weight
403.52
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
Benzamide, N- (2-aminophenyl) -4-[1-[ (1,3-dimethyl-1H-pyrazol-4-yl) methyl]-4-piperidinyl]-